Thanks good info!!

It’s not good, not bad. Depends entirely on your perspective. Bad for RUO suppliers: When peptides move off the FDA shortage list or get approved status changes, the research peptide market typically shrinks. Less access, fewer sources, potentially higher prices in that space. Good for pharmaceutical companies: Absolutely. They get market protection, exclusivity, and the ability to charge whatever they want. This is a win for Big Pharma. Bad for compound pharmacies: Actually, this usually hurts them too. When peptides come off the shortage list, compounding pharmacies lose the legal ability to compound them. So the expensive compound pharmacy pricing you’re seeing now? That might not even be an option anymore for some of these peptides. Mixed for us (the end users): You get better quality control and FDA oversight, which is good. But you also get way higher prices, limited access, and insurance battles. Trade-offs. The reality is this push benefits pharmaceutical companies more than anyone else. They want to lock down the peptide market, control pricing, and eliminate competition from both RUO suppliers and compounding pharmacies. So yeah, perspective matters. If you’re a pharma exec, this is great news. If you’re someone trying to access affordable peptides for research or therapeutic use, not so